| | 90 | == Agenda == |
| | 91 | |
| | 92 | 1. [wiki:Research/DesignStudy/SteeringGroup/2020-06-05 Notes of last meeting and actions arising:] |
| | 93 | * **KL**: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme. |
| | 94 | * **Ongoing.** Need to step up the priority of this activity as we prepare the EPSRC proposal. |
| | 95 | * **KL/CB**: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF. |
| | 96 | * **Stands.** This meeting is necessary and, probably, should include Strathclyde and Belfast. |
| | 97 | * **KL/KK** to collaborate on the development for a proposal for such a meeting on the timescale of November 2020. |
| | 98 | * **Stands.** Agenda item. |
| | 99 | * **KL** Send out diary invitation straight away to get it into the diary. |
| | 100 | * **Done.** |
| | 101 | |
| | 102 | 2. [raw-attachment:2020-07-03-Progress-update.pdf Update on progress]: KL \\ |
| | 103 | |
| | 104 | 3. Discussion of SG composition: KL/All |
| | 105 | |
| | 106 | 4. [https://epsrc.ukri.org/funding/calls/second-call-for-transformative-healthcare-technologies-pre-announcement-and-engagement-event/ EPSRC Transformative Healthcare Technologies call]: KL/All |
| | 107 | * Dealing with feedback from our 2019 submission: \\ |
| | 108 | "//Engagement with patients, clinicians and industry could have been strengthened//" |
| | 109 | - Patient engagement: |
| | 110 | - Actions taken to date; |
| | 111 | - Need for local action by partner; |
| | 112 | - Subsequent coordination |
| | 113 | - Clinician engagement: |
| | 114 | - Actions taken to date; |
| | 115 | - Need for local action by partner; |
| | 116 | - Subsequent coordination |
| | 117 | - Industrial engagement: |
| | 118 | - Actions taken to date; |
| | 119 | - Discussion of next steps |
| | 120 | * Slides to initiate discussion of: |
| | 121 | - Scope; |
| | 122 | - Initial discussion of work packages; |
| | 123 | - Stakeholders from whom we should be seeking support; |
| | 124 | * Next steps discussion |
| | 125 | |
| | 126 | 5. Follow-up Discussion of dedicated advanced diagnostics and instrumentation for the //in vitro// and //in vivo// end stations: KL/all |
| | 127 | |
| | 128 | 6. DONMs \\ |
| | 129 | * 04 Sep 2020; 10:00 BST |
| | 130 | |
| | 131 | 7. AoB \\ |
| | 132 | |
| | 133 | ---- |
